



Neurotune completes next funding round

Schlieren, 29th July 2008. Neurotune AG, a Swiss biopharmaceutical company, announces the closing of the fourth funding round. Another single-digit million Swiss francs will accrue to the company. The company will use the increase in capital to advance the development of its therapeutical approach to treat sarcopenia and along with this the diagnostic methods. Part of the capital will be used to extend a developmental pipeline.

The company focuses on the development of a drug to treat sarcopenia, i.e. age-related muscle atrophy. More than ten million people worldwide are affected by this disease. Appropriate lead candidates have been identified already and presumably the preclinical development of the most promising product candidates will start shortly. In addition, the company will intensify its efforts to establish a biomarker for early and decisive clinical diagnosis of sarcopenia, because the currently used methods are inefficient and labor-intensive.

CONTACT

neurotune ag

Mrs. Theres Oesch
Assistant to the CEO
Wagistrasse 27 a
8952 Schlieren (Zurich)
Switzerland
www.neurotune.com
Phone +41 44 200 21 95
Fax +41 44 200 20 10
theres.oesch@neurotune.com

Media enquiries

Dr. Holger Bengs
Biotech Consulting
Phone +49 69 6199 4273
Fax +49 69 6199 4249
info@holgerbengs.de

ABOUT NEUROTUNE AG

Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has its seat in Schlieren (Zurich), Switzerland.

Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy – Sarcopenia, and a corresponding biomarker.

ABOUT SARCOPENIA

With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy – Sarcopenia – is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.

The treatment of Sarcopenia is a growing market with no available causal treatment.

This press release contains forward-looking statements. Neurotune disclaims any intent or obligation to update these forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected size and timing of closing of the registered direct offering. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in meeting closing conditions, and actions of regulatory authorities relating to the Neurotunes' shelf registration statement and the registered direct offering. For further information regarding these and other risks related to Neurotunes' business, investors should consult Neurotune.